Measurement of p-Nitrophenol in the Urine of Residents Whose Homes Were Contaminated with Methyl Parathion

Dana B. Barr,1 Wayman E. Turner,1 Emily DiPietro,1 P. Chery McClure,1 Samuel E. Baker,1 John R. Barr,1 Kimberly Gehle,2 Raymond E. Grissom Jr.,2 Roberto Bravo,1 W. Jack Driskell,1 Donald G. Patterson Jr.,1,3 Robert H. Hill Jr.,1 Larry L. Needham,1 James L. Pirkle,1 and Eric J. Sampson1

1National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; 2Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA

During the last several years, illegal commercial application of methyl parathion (MP) in domestic settings in several U.S. Southeastern and Midwestern States has affected largely inner-city residents. As part of a multiagency response involving the U.S. Environmental Protection Agency (U.S. EPA), the Agency for Toxic Substances and Disease Registry (ATSDR), and state and local health departments, our laboratory developed a rapid, high-throughput, selective method for quantifying p-nitrophenol (PNP), a biomarker of MP exposure, using isotopic dilution high-performance liquid chromatography–tandem mass spectrometry. We measured PNP in approximately 16,000 samples collected from residents of seven different states. Using this method, we were able to receive sample batches from each state; prepare, analyze, and quantify the samples for PNP; verify the results; and report the data to the health departments and ATSDR in about 48 hr. These data indicate that many residents had urinary PNP concentrations well in excess of those of the general U.S. population. In fact, their urinary PNP concentrations were more consistent with those seen in occupational settings or in poisoning cases. Although these data, when coupled with other MP metabolite data, suggest that many residents with the highest concentrations of urinary PNP had significant exposure to MP, they do not unequivocally rule out exposure to PNP resulting from environmental degradation of MP. Even with their limitations, these data were used with the assumption that all PNP was derived from MP exposure, which enabled the U.S. EPA and ATSDR to develop a comprehensive, biologically driven response that was protective of human health, especially susceptible populations, and included clinical evaluations, outreach activities, community education, integrated pest management, and decontamination of homes.

Keywords: mass spectrometry, methyl parathion, p-nitrophenol, urine. Environ Health Perspect 110(suppl 6):1085–1091 (2002).

http://ehpnet1.niehs.nih.gov/docs/2002/suppl-6/1085-1091barr/abstract.html

In the fall of 1994, officials in Ohio discovered that methyl parathion (MP) had been used for domestic pest control, primarily in inner-city homes (1–3). Further investigations uncovered that an unlicensed operator had illegally applied MP in hundreds of homes for cockroach control. This event resulted in costly government-subsidized evacuations and home decontaminations (4,5).

Since the episode in Ohio, similar incidents have occurred in seven other Southeastern and Midwestern States. To aid in prioritizing evacuation and decontamination efforts, the Agency for Toxic Substances and Disease Registry (ATSDR) asked our laboratory to provide biomonitoring data for residents affected by these illegal applications. We developed a rapid, high-throughput method for quantifying a biomarker of MP exposure and applied this method to assess MP exposure in residents of contaminated homes.

MP is a highly toxic organophosphate insecticide. Since its introduction in 1952, MP has been used primarily for the control of boll weevils on cotton (6). Its mode of action, common to all organophosphate insecticides, is the competitive inhibition of acetylcholinesterase, an enzyme responsible for the breakdown of the neurotransmitter acetylcholine (7,8). MP is classified as a restricted-use pesticide by the U.S. Environmental Protection Agency (U.S. EPA) (6). It is licensed only for use in outdoor settings, and workers may not reenter fields sprayed with MP for at least 4–5 days (9). When applied properly in agricultural settings where it is exposed to water and ultraviolet (UV) light, MP has an environmental half-life of days or weeks (6,10). When applied indoors, the environmental half-life may increase substantially.

MP has a biological half-life in animals of 7–17 hr (11,12). Upon exposure and subsequent bodily absorption, MP is rapidly metabolized (Figure 1) to biologically active methyl paraoxon. Methyl paraoxon can chemically bind acetylcholinesterase, which can ultimately result in a variety of clinical outcomes including headaches, seizures, respiratory depression, paralysis, and death (5). Further metabolism can result in the urinary excretion of dimethylthiophosphate (DMTP), dimethylphosphate (DMP), and p-nitrophenol (PNP), either as the free phenol or as its glucuronide or sulfate ester (13). The dialkylphosphate metabolites of MP are largely nonspecific because they are potential metabolites of about 75% of the organophosphate pesticides registered with the U.S. EPA (14). Although it is also a metabolite of parathion, nitrobenzene, and a few similar compounds, PNP is considered a more specific biomarker of exposure to MP than the dialkylphosphate metabolites (13,15). However, urinary PNP can also result from exposure to environmental PNP resulting from the natural environmental degradation of MP or parathion. After an acute exposure, the majority of DMTP, DMP, and PNP is excreted in urine within a few days (16–19). However, chronic exposure to MP, as with any nonpersistent organic toxicant, can result in steady-state excretion of the metabolites.

Measurements of the change in acetylcholinesterase activity from an individual’s baseline (preexposure) acetylcholinesterase activity is considered the “gold standard” measurement for clinical assessment and management of organophosphate intoxication (20). Unfortunately, in nonoccupational exposures, baseline activity levels are difficult to obtain because usually an individual is seen by a clinician after the exposure has occurred. Furthermore, acetylcholinesterase depression measurements typically lack the sensitivity to detect low-level exposures.

Typically, PNP has been quantified in urine as a more sensitive biomarker of exposure to MP or parathion. These methods use
high-performance liquid chromatography (HPLC) with UV or diode array detection (21,22) or gas chromatography (GC) with electron capture detection (23) and have limits of detection ranging from 20 to 500 µg/L. These methods lack the selectivity or the sensitivity to measure trace amounts of PNP in urine. More recently, our laboratory reported a multianalyte method for the selective analysis of 12 urinary pesticide metabolites, including PNP, at the low microgram per liter level (24). This method combined a solvent extraction of PNP from urine, a chemical derivatization of PNP to its chloropropyl ether, and a selective analysis using GC–tandem mass spectrometry (GC–MS/MS). The major limitation of this method was the lengthy chemical derivatization step (6 hr) required to adequately analyze for the multiple analytes, which severely limited the analytical throughput of the method. With our multianalyte method, 25 samples could be analyzed in 4 days. This was equivalent to 1 sample per 4 hr. To improve the analytical throughput without sacrificing method sensitivity or selectivity, we opted to use HPLC–MS/MS, allowing us to eliminate the need for chemical derivatization.

We report our high-throughput and selective method for the quantification of urinary PNP. Our new method is capable of analyzing 160 samples in 2 days, or 1 sample every 18 min, representing an almost 13-fold increase in throughput. Using this method, we were able to receive sample batches from state and local health departments; prepare, analyze, and quantify the samples for PNP; verify the results; and report the data to health departments and ATSDR in about 48 hr. We also report data obtained from people exposed to MP or environmental PNP as a result of its illegal residential application in seven Southeastern and Midwestern States. As a result of the epidemic nature of MP exposure in the past several years, we have accumulated what appears to be the largest volume of biological monitoring data for a single pesticide exposure cohort.

**Materials and Methods**

**Materials**

All chemicals unless otherwise indicated were obtained in the purest form commercially available from JT Baker Chemical Co. (Phillipsburg, NJ, USA). PNP (gold label 99+% purity) was purchased from Aldrich Chemical Co. (Milwaukee, WI, USA), and ring-13C6-PNP (98% chemical purity, 99.99% isotopic purity) was purchased from Cambridge Isotope Laboratories (Andover, MA, USA). The enzyme β-glucuronidase/sulfatase from Helix pomatia was purchased from Sigma Chemical Co. (St. Louis, MO, USA). The gases for MS were obtained from Holox (Norcross, GA, USA) or Air Products and Chemicals Inc. (Atlanta, GA, USA) and had a minimum purity of 99.999%. Our solvents, including water, were analytic grade and were obtained from Burdick and Jackson Co. (Muskegon, MI, USA). All chemicals and solvents were used without further purification. Reagents were prepared with bottled water according to standard laboratory procedures.

**Standard Preparation and Characterization**

**Calibration standards.** A PNP stock solution was prepared by dissolving 18 mg PNP in dimethylformamide (DMF). A 13C6-PNP stock solution was prepared by dissolving 10 mg ring-13C6-PNP in DMF. The PNP and 13C6-PNP stock solutions were combined and diluted with DMF to create eight standard sets whose concentrations encompassed the linear range of the method (10–800 µg/L in urine or 50–2500 ng on column). The stocks and diluted standard sets were stored at –20°C.

**Internal standard.** A diluted 13C6-PNP solution was prepared from the stock such that a 25-µL aliquot gave an approximate 150-µg/L concentration in 3 mL urine. The 13C6-PNP concentration was adjusted to be close to the expected or measured value to minimize error. Diluted 13C6-PNP standards were divided into aliquots sufficient for two analytical runs and were stored at –20°C until used.

**Quality control materials.** Quality control (QC) materials were prepared in-house from a base urine pool obtained from multiple donors. The base urine was homogenized, then split into three pools. One pool was not enriched and thus reflected the endogenous, or native, concentration of PNP in the urine. The other two pools were enriched with different levels of PNP. Thus, QC pools with native, low (approximately 75 µg/L), and high (approximately 150 µg/L) concentrations were obtained. All QC pools were mixed thoroughly for 24 hr following enrichment. The pools were filtered through a sterile membrane apparatus (0.2 µm pore size). The filtered urine was dispensed in 20-µL aliquots into sterile bottles. The bottles were capped, labeled, and stored at –20°C until used. All QC pools were characterized to define the mean concentration and the 95th and 99th confidence intervals of PNP by the analysis of at least 20 repeat measurements. QC concentrations were evaluated using standard Westgard multirules (25).

**Sample Preparation**

Three-milliliter aliquots of urine were spiked with 13C6-PNP. The urine samples were diluted with an equal volume of 0.1 M acetate buffer (pH 4.5) containing approximately 430 µM β-glucuronidase/sulfatase. The sample tubes were capped and inverted to mix. The urine/enzyme solutions were allowed to incubate at 37°C overnight (about 17 hr) to liberate the PNP from the glucuronides or sulfate esters. The hydrolysates were acidified with 200 µL 3 M HCl to a
pH of approximately 2. Ten milliliters of dichloromethane was added to each sample and the tubes were inverted 10 times for extraction. The samples were centrifuged at 2,000 rpm for 15 min to adequately separate the organic and aqueous layers. The organic layers were dried over anhydrous sodium sulfate and transferred to clean sample tubes. As a keeper solvent, 100 µL DMF was added to each extract and they were concentrated to 100 µL using a TurboVap concentrator (Zymark Corporation, Hopkinton, MA) with 15 psi nitrogen head pressure at 37°C. The concentrated extracts were transferred to HPLC autosampler vials for analysis.

Instrumental Analysis

The HPLC-MS/MS analysis was performed with an HP1090L HPLC (Hewlett-Packard Co., Palo Alto, CA, USA) connected in tandem to a TSQ-7000 triple quadrupole mass spectrometer (Finnigan MAT Instruments, San Jose, CA, USA) equipped with an atmospheric pressure ionization (API) interface. Separation was achieved on a 15 cm × 4.6 mm OD5 C18 column (Burdick and Jackson) with 5-µm particles, which was preceded inline by a 5-µm stainless steel frit to prolong the column lifetime. The solvent system was isocratic, consisting of 55:45 0.1% aqueous ammonium bicarbonate (pH 7.8):0.1% methanolic ammonium bicarbonate.

Negative atmospheric pressure chemical ionization MS/MS was achieved by using nitrogen as a sheath gas and argon as the collision gas. No API auxiliary gas was used. The pressure of nitrogen entering the API unit was kept constant at 40 psi (276 kPa). The argon gas pressure was 2 × 10^{-5} T (0.27 Pa). The API vaporizer and capillary temperatures were 400°C and 200°C, respectively. The discharge of the corona needle was 5 µA. The collision offset was at 24 V for optimal fragmentation. The electron multiplier voltage ranged from 1,800 to 2,400 V.

During an analysis, eight product ions were monitored in a multiple reaction monitoring (MRM) experiment at a scan time of 0.6 sec/ion. One quantification and one confirmation ion were monitored for each of the native PNP and the 13C6-PNP. In addition, one MS/MS transformation each was monitored for the PNP dimer and the 13C6-PNP dimer and two MS/MS transformations for the mixed dimer. Table 1 lists the specific transformations monitored. The appropriate MRM specifications were recorded into an acquisition program initiated immediately upon injection of 10 µL of the sample extract by the HPLC autoinjector. The total analysis time per sample was about 3 min.

Typically, one analytical run consisted of 80 samples and was prepared for analysis by one analyst. Of these samples, 10% were QC materials, 10% were analytical standards, and 80% were unknown samples. One blank urine sample was analyzed per run. One instrument operated by one analyst was automated to analyze up to two analytical runs (160 samples) per day. We routinely analyzed 160 samples per day with one instrument and three to five analysts. Therefore, the total sample throughput was 1 sample per 18 min, or 30–55 samples per analyst day.

Data Processing/Analysis

Data were automatically processed by software supplied with the mass spectrometer. Each ion of interest was automatically selected, retention times were calculated, and the area was integrated. All data were checked for interferences, peak selection, and baseline determinations and were corrected if found in error. The HPLC-MS/MS technique is highly selective such that an analyte is identified as PNP only if it meets the following criteria: a) elutes at a specified retention time; b) coelutes with the internal standard; c) possesses the same nominal mass as PNP; d) produces the same fragment ions as PNP; and e) has the same relative abundance (ratio of fragment ions) of fragment ions as PNP. Because of this specificity, interferences were rare. However, any interferences were easily recognizable because of a dramatic change in the ratio of the quantification ions to the confirmation ions of either the native analyte or the internal standard. When necessary, the data were reanalyzed to reflect these corrections.

The data were downloaded into an ASCII file and transferred from the UNIX-based operating system on the TSQ-7000 to a PC via an ethernet connection. The data were imported into an R:BASE (Microrim, Redmond, WA, USA) database specifically designed for this analysis. The ratios of the quantification and confirmation ions were calculated. If the ratios were outside the 99% confidence limits, the analysis was repeated. If the ratios remained outside the 99% confidence limits in the second analysis, the data were considered unacceptable. All statistical analyses including QC evaluations were performed with SAS statistical software (SAS Institute, Inc., Cary, NC, USA).

Quantification

A calibration curve was constructed with the log_{10} of eight different analyte concentrations plotted against the log_{10} of the analyte response factor. The lowest standard concentration was near the method limit of detection (LOD) to ensure linearity at the low concentration end. The response factors (area/area internal standard) were calculated according to established methods (24,26). There were no apparent contributions of the isotope to the native ions and native to the isotope ion. A linear regression analysis of the calibration plot provided a slope and intercept from which concentrations of unknown samples could be calculated. Over the duration of this study, approximately 300 repeat determinations were performed for each point on the calibration curve.

Method validation. The analytical LOD of PNP was calculated as 3σo, where σo is the value of the standard deviation as the concentration approaches zero. The σo was determined as the y-intercept of a best-fit line of a plot of standard deviation of the standard samples used in the calibration curve versus the concentration (27).

Well-characterized pooled urine samples were enriched with a known amount of the native PNP standard and prepared according to the procedure outlined above. After the extraction, a known amount of 13C6-PNP was added to each eluent, and the samples were analyzed. A control sample, which was a urine extract that did not contain endogenous PNP, was enriched with the same amount of native and labeled PNP. The recovery of PNP from the extract was calculated as a percentage of the control PNP concentration, as the 13C6-PNP corrected for any variation in instrumental response.

The method accuracy was evaluated by enriching urine samples with a known amount of native standard, preparing and analyzing the samples, then comparing the calculated concentration of the samples with the expected concentration. A linear regression analysis was performed on a plot of the calculated concentration versus the expected concentration. A slope of 1.0 is indicative of 100% accuracy.

### Table 1. MS/MS specifications for MRM experiment.

| Species     | Precursor Ion | Product Ion | Neutral Loss | Purpose of Ion |
|-------------|---------------|-------------|--------------|----------------|
| PNP         | 138           | 108         | NO           | Quantification |
| PNP         | 138           | 92          | NO2          | Confirmation   |
| 13C6-PNP    | 144           | 114         | NO           | Quantification |
| 13C6-PNP    | 144           | 98          | NO2          | Confirmation   |
| 2PNP        | 277           | 138         | 13C6-PNP     | QA             |
| 2PNP-13C6-PNP | 283         | 136         | 13C6-PNP     | QA             |
| 2PNP-13C6-PNP | 283         | 144         | PNP          | QA             |
| 2PNP-13C6-PNP | 289         | 144         | 13C6-PNP     | QA             |

QA, monitored for quality assurance.
The method precision was determined by calculating the coefficient of variation (CV) of repeat measurements of the QC materials. At least 400 repeat measurements over a 2-year period were used in the calculations. In addition, both interday and intraday variation were determined.

Cross-Instrument Validation

To validate the use of additional TSQ-7000 mass spectrometers in our analyses, we analyzed at least 50 samples that had been previously run on a validated mass spectrometer. These samples consisted of standards, QC materials, and unknown samples. The data from these analyses were plotted against the previously obtained data. The slope of the resultant linear regression analysis had to be within ±5% of 1.00 to cross-validate the new mass spectrometer.

Biological Monitoring of Methyl Parathion Exposure in Affected Residents

Concentrations of PNP were determined in the urine of people living in homes illegally contaminated with MP. State health officials collected urine specimens in 30-mL sterile Qorpak bottles (Qorpak, Pittsburgh, PA, USA). Specimen bottles were closed with polytetrafluoroethylene-lined screw caps, and the bottles were labeled with an appropriate specimen identification number. The identification number consisted of a five-character numeric code unique to the state and residence, followed by a three-character alphanumeric code that represented the particular individual tested and time of collection (i.e., A.M. or P.M.). These samples were shipped on dry ice overnight to our laboratory for testing.

Testing results were returned to the states within 48 hr, on average. These results were used to prioritize the relocation and decontamination efforts and to follow exposures over time to individuals in homes that were not decontaminated. The specific biologically driven action criteria for relocation and decontamination have been published elsewhere (28). Briefly, three action levels were defined (no further action needed, urine monitoring, relocation), and the urinary PNP concentrations required for these actions were broken into three categories (<1 year of age or pregnant, 1–15 years of age, ≥16 years of age). Urinary PNP concentrations resulting in continued monitoring ranged from 25 to 600 µg/L ppb, and those resulting in relocation ranged from 50 to 600 µg/L, both depending upon the age/pregnancy category.

Results and Discussion

Solvent extraction with dichloromethane proved to be simple and efficient for extracting PNP from the urine sample. The recovery of PNP at 5 and 10µg/L was 85 ± 8% and 70 ± 3%, respectively. This simple extraction step, when performed in batches of 80 samples by one analyst, was completed in approximately 3 hr. Although the cleanup procedure was not highly selective, its simplicity allowed a high sample throughput for the method and minimized the errors normally associated with nonautomated, complex cleanup procedures.

Addition of an isotopically labeled standard (13C6-PNP) prior to sample manipulation, a technique known as isotope dilution (29), afforded us many advantages. Chemically, 13C6-PNP behaves almost identically to PNP, but they are distinguishable based upon the 6-atomic mass unit (amu) difference in their masses and respective fragment ions (Figure 2). For this reason, the ratio between their ions can internally correct for recovery of PNP in each individual sample. This eliminates the need for recovery surrogates. The automatic recovery correction reduces the error associated with the measurement and ultimately increases the method sensitivity.

As shown in the spectra in Figure 2, the major fragment ions produced during the MS/MS transformation correspond to the neutral loss of [NO] and [NO2]. These losses, although common to most nitroaromatic compounds, provided a great deal of selectivity to our analysis. Because we observed some degree of dimer formation (i.e., 2PNP, 213C6-PNP, and PNP-13C6-PNP) during MS analysis, we also monitored the MS/MS transformations of the dimers to their respective monomers.

The method LOD was calculated to be 25 µg/L. Although this LOD was higher than previously published methods (23,24), it was suitable for categorizing samples into the various priority levels required for public health intervention. In subsequent studies we were able to lower the method LOD to 81 ng/L as calculated from calibration standards spiked into urine. We obtained over a 300-fold increase in sensitivity by modifying only a few mass spectral parameters. More specifically, by increasing the vaporizer and capillary temperatures by up to 50°C, the dimer formation became almost negligible. This increased the amount of the monomers available for the MS/MS transformations used in quantification and decreased the number of transformations monitored during the chromatographic retention window. These changes did not alter the calibration of the analytical system.

A calibration plot is shown in Figure 3. The PNP analysis was linear over two orders of magnitude, with an r2 = 0.997. Similar calibration plots were obtained on multiple instruments, providing us flexibility and added resources when the sample load was

Figure 2. Both the native PNP (A) and the 13C6-labeled PNP (B) fragment are almost identical but are distinguished based upon their 6-atomic mass difference. The predominant neutral losses are NO and NO2.

Figure 3. A calibration plot for PNP shows linearity over almost three orders of magnitude. The r2 value is 0.999.
affected residents and decontamination and restoration of their homes (5).

A summary of the urinary PNP concentrations (micrograms per liter units) in about 16,000 samples is shown in Table 3. The creatinine-adjusted data for the same individuals are also shown. The mean concentration differed significantly from the median concentration for both the volume-based and creatinine-adjusted data, indicating that the data distribution was skewed. The mean PNP concentration was roughly 15-fold greater than the 95th percentile (upper limit) of the reference range (5.2 µg/L) (30). The median concentration was about 6 times the upper reference range; however, the median was well below the maximum concentration observed in the general U.S. population. The creatinine-adjusted mean was about an order of magnitude higher than the upper reference range (3.8 µg/g creatinine), whereas the creatinine-adjusted median was about 4 times higher.

Concentrations were detectable in about 57% of the samples measured. This detection frequency is slightly higher than that observed in the general U.S. population (41%) (30); however, the lower limit of reportable data for this study was 25 times higher than the LOD of the reference range study. If we were to impose the higher limit of detection on the general population data, <1% of the samples would have had detectable urinary PNP concentrations. Less than 1% of the samples contained interfering substances that precluded the report of their PNP concentrations.

PNP concentrations categorized by state and compared with incidental, occupational, and poisoning concentrations are shown in Figure 5. The ranges shown by state include multiple discrete samples from the same individuals, both adults and children. The upper range of PNP concentrations in Illinois, Louisiana, Mississippi, and Tennessee were within the reported range of PNP levels encountered in occupational exposures. In addition, many of the samples tested in these states had PNP levels within the ranges seen in both nonfatal and fatal poisoning incidences. No fatalities were reported in any of the states tested.

Urinary PNP can result from exposure to parathion, MP, environmental PNP (as the degradation product of MP), and several other sources. Therefore, we verified that extremely elevated PNP concentrations (i.e., upper 1% of the distribution) in urine samples were, at least in part, a result of MP exposure by measuring the additional MP metabolites DMP and DMTP in the same urine samples. These metabolites were quantified using an isotope dilution GC–MS/MS method (31). There was a strong positive correlation between summed dialkylphosphate molar concentrations and PNP molar concentrations ($r = 0.78$, $p = 0.001$). When evaluated by the individual dialkylphosphate, both DMP and DMTP remained highly correlated with PNP concentrations ($r = 0.90$, $p = 0.0001$ and $r = 0.39$, $p = 0.007$, respectively). As seen in Figure 6, two extremely high values appear to skew the correlation of DMTP and PNP. However, when these two high values are removed, a good correlation...
(Pearson coefficient = 0.75, \(p = 0.0001\)) still exists (Figure 6 inset). In about 65% of the samples tested, DMP concentrations were greater than DMTP concentrations in the same sample. The DMP and DMTP concentrations ranged from less than the LOD to 145 \(\mu\)g/L and 460 \(\mu\)g/L, respectively. These data are consistent with the reported abundance of the dialkylphosphate metabolites of MP after occupational exposures (32–34). However, both DMP and DMTP concentrations in the samples tested had geometric means that were 11 and 5 times higher, respectively, than the geometric means of these same metabolites in the general population published in the Centers for Disease Control and Prevention National Report on Exposure to Environmental Chemicals (35). Because the dialkylphosphate metabolites are unlikely to be effectively absorbed through the skin because of their high polarity, these data suggest that the urinary PNP measured in these samples resulted, in part, from exposure to MP.

In many states, urine specimens were collected in both morning and evening. This sampling strategy was devised to evaluate whether a spot sample collected during the day would be representative of a 24-hr collection. Multivariate and paired bivariate analyses of the cumulative data and data categorized by state showed no significant difference between morning and evening PNP concentrations whether or not the data were creatinine adjusted. In fact, there was a moderate yet significant positive Pearson correlation \((r = 0.39, \text{volume-based}, r = 0.44\) creatinine adjusted, \(p = 0.0001\)) between cumulative morning and evening PNP concentrations for both volume-based and creatinine-adjusted analyses. In addition, some individual states showed strong correlations between morning and evening samples. These data suggest that similar PNP concentrations would be obtained regardless of the collection time.

In many states, residents whose urinary PNP concentrations placed them in the middle range were monitored on a quarterly basis to assess any changes in exposure over time. A paired bivariate analysis showed a significant increase in urinary PNP concentrations after the first 3 months from a mean of 18 \(\mu\)g/g creatinine to a mean of 27 \(\mu\)g/g creatinine \((p = 0.0021)\). For the next 6 months there was no significant change in urinary PNP concentrations \((p > 0.05)\). However, after the next 3-month interval, the levels dropped significantly to 20 \(\mu\)g/g creatinine \((p = 0.0032)\), nearer to the first-quarter values.

**Conclusions**

We have developed a sensitive and selective method for the quantification of PNP using isotope dilution HPLC–MS/MS. We applied this method to the analysis of about 16,000 samples collected from residents exposed to MP and/or PNP from their homes, which were contaminated by the illegal commercial application of MP. These data indicate that these residents had urinary PNP levels well in excess of those of the general U.S. population. These results enabled public health officials to implement a comprehensive, biologically driven response that included prioritization of relocation and decontamination efforts so that those who were most at risk were provided for most urgently.

**REFERENCES AND NOTES**

1. Rubin C, Esteban E, Hill RH Jr., Pearce K. Introduction—The methyl parathion story: a chronicle of misuse and preventable human exposure. Environ Health Perspect 110(suppl 6):1037–1040 (2002).
2. Rubin C, Esteban E, Kieszak S, Hill RH Jr., Dunlop B, Yacovac R, Trotier J, Boylan K, Tomaszewski T, Pearce K. Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995–1996. Environ Health Perspect 110(suppl 6):1047–1051 (2002).
3. Esteban E, Rubin C, Hill R, Olson D, Pearce K. Association between indoor residential contamination with methyl parathion and urinary para-nitrophenol. J Expo Anal Environ Epidemiol 6:375–387 (1996).
4. ATSDR. National Alert: Illegal use of methyl parathion. Agency for Toxic Substances and Disease Registry. Available: http://www.atsdr.cdc.gov/alerts/61213.htm [accessed 26 January 2002].
5. Leikin JB, Paloucek FP. Poisoning and Toxicology Compendium with Symptoms Index. Hudson, OH:Lexi-Comp Inc., 1998;714–715.
6. ATSDR. Methyl Parathion. Toxicological Profile. Atlanta, GA:Agency for Toxic Substances and Disease Registry. 2001.
7. Nigg HN, Knack JB. Blood cholinesterases as human biomarkers of organophosphorus pesticide exposure. Rev Environ Contam Toxicol 163:29–111 (2000).
8. Ware GW. The Pesticide Book. Fresno, CA:Thomas Publications, 1989.
9. U.S. EPA. Methyl parathion risk management decision. Office of Pesticide Programs. U.S. Environmental Protection Agency. Available: http://www.epa.gov/pesticides/citizens/mpfactsheet.htm [accessed 27 January 2002].
10. Pappas CJ, Kyriakidis NB, Athanasopoulos PE. Degradation of parathion methyl on field-sprayed apples and stored apples. J AOAC Int 82:399–363 (1999).
11. De Schryver E, De Reu L, Belpaire F, Willems J. Environmental Chemicals (32–34).
12. Abu-Qare AW, Abdel-Rahman AA, Ahmad H, Kishk AM, Abou-Dania MB. Absorption, distribution, metabolism and excretion of daily oral doses of \(^{14}C\)parathion in male and female rats. Toxicol Appl Pharmacol 1:254–269 (1975).
13. Benke GM, Murphy SD. The influence of age on the toxicology and metabolism of methyl parathion and parathion in male and female rats. Toxicol Appl Pharmacol 31:254–269 (1975).
14. Whyatt RM, Barr DB. Measurement of organophosphate metabolites in postpartum meconium as a potential bio-marker of prenatal exposure: a validation study. Environ Health Perspect 109:417–420 (2001).
15. Barr DB, Needham DL. Analytical methods for biological monitoring of exposure to pesticides: a review. J Chromatogr B 778:15–29 (2002).
16. Morgan DP, Hetzler HL, Schach EF, Lin LS. Urinary excretion of para-nitrophenol and alkyl phosphates following ingestion of methyl or ethyl parathion by human subjects. Arch Environ Contam Toxicol 6:159–173 (1977).
17. International Agency for Research on Cancer. Methyl parathion. IARC Monogr Eval Carcinog Risk Chem Hum 30:131–152 (1983).
18. Braeckman RA, Audenaert F, Willems JL, Belpaire FM, Bogaert MG. Toxicokinetics of methyl parathion and parathion in the dog after intravenous and oral administration. Arch Toxicol 59:209–220 (1987).
19. Abu-Qare AW, Abou-Dania MB. Urinary excretion of metabolites following a single dermal dose of \(^{14}C\)parathion in pregnant rats. Toxicol Appl Pharmacol 150:119–127 (2000).
20. Abu-Qare AW, Abou-Dania MB. Urinary excretion of metabolites following a single oral dose of \(^{14}C\)parathion in pregnant rats. Environ Health Perspect 110(suppl 6):1037–1040 (2002).
21. Michaels P. Determination of \(p\)-nitrophenol in serum and urine by enzymatic and non-enzymatic conjugate hydrolysis and HPLC. Application after parathion intoxication (in
22. Cho Y, Matsuoka N, Kamiya A. Determination of organophosphorous pesticides in biological samples of acute poisoning by HPLC with diode-array detector. Chem Pharm Bull 45:737–740 (1997).

23. Edgell KW, Erb EJ, Wesselman RJ, Longbottom JE. Gas chromatographic/electron capture detection method for determination of chlorinated acids in water: collaborative study. J AOAC Int 76:1098–1112 (1993).

24. Hill RH Jr, Shealy DB, Head SL, Williams CC, Bailey SL, Greg M, Baker SE, Needham LL. Determination of pesticide metabolites in human urine using an isotope dilution technique and tandem mass spectrometry. J Anal Toxicol 19:323–329 (1995).

25. Westgard JO. Westgard QC multirules. Available: http://www.westgard.com/mltirule.htm [accessed 25 January 2002].

26. Barr DB, Ashley DL. A rapid, sensitive method for the quantitation of N-acetyl-S-(2-hydroxyethyl)-L-cysteine in human urine using isotope dilution HPLC-MS-MS. J Anal Toxicol 23:96–104 (1998).

27. Taylor JK. Quality Assurance of Chemical Measurements. Boca Raton, FL: CRC Press, 1987.

28. McCann KG, Moomey CM, Runkle KD, Hryhorczuk DG, Clark JM, Barr DB. Chicago area methyl parathion response. Environ Health Perspect 110(suppl 6):1075–1078 (2002).

29. Colby BN, McCaman MW. A comparison of calculation procedures for isotope dilution determinations using gas chromatography mass spectrometry. Biomed Mass Spectrom 6:225–230 (1979).

30. Hill RH Jr, Head SL, Baker S, Gregg M, Shealy DB, Bailey SL, Williams CC, Sampson EJ, Needham LL. Pesticide residues in urine of adults living in the United States: reference range concentrations. Environ Res 71:99–108 (1995).

31. Bravo R, Driskell WJ, Whitehead RD, Needham LL, Barr DB. Quantification of dialkyl phosphate metabolites of organophosphates pesticides in human urine using GC-MS/MS with isotope dilution quantification. J Anal Toxicol 26:245–252 (2002).

32. Apres C, Sciarra G, Sartorelli P, Desideri E, Amati R, Sartorelli E. Biological monitoring of exposure to organophosphorus insecticides by assay of urinary alkylphosphates: influence of protective measures during manual operations with treated plants. Int Arch Occup Environ Health 66:333–338 (1994).

33. Davies JE, Peterson JC. Surveillance of occupational, accidental, and incidental exposure to organophosphate pesticides using urine alkyl phosphate and phenolic metabolite measurements. Ann NY Acad Sci 837:257–268 (1997).

34. Schneider F, Steenland K, Hernandez B, Wilson B, Krieger R, Spencer J, Margetich S. Monitoring peach harvest workers exposed to azinphosmethyl residues in Sutter County, California, 1991. Environ Health Perspect 102:586–585 (1994).

35. CDC. National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: Centers for Disease Control and Prevention. Available: http://www.cdc.gov/nceh/dfs/report/ [accessed 10 January 2002].

36. Arteberry JD, Durham WF, Elliot JW, Wolfe HR. Exposure to parathion: measured by blood cholinesterase levels and urinary excretion of p-nitrophenol. Arch Environ Health 3:476–485 (1961).

37. Durham WF, Wolfe HR, Elliot JW. Absorption and excretion of parathion by spraymen. Arch Environ Health 24:381–387 (1972).

38. Roan CC, Morgan DP, Cook N, Paschal EH. Urinary excretion of metabolites in persons occupationally exposed to pesticides. Bull Environ Contam Toxicol 4:362–369 (1969).